Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy-Reference-Cited by-同舟云学术

Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy

Published:2005-07 Issue:6 Volume:7 Page:244-249
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

García-Girón Carlos,Palomo Andrés García,López Carmen Alonso,Carbonero Ángel León,Urena Miguel Méndez,Cebrián Encarna Adróver,Galíndez Ramón Barceló,Yustos Mónica Arroyo,Gallego José Álvarez

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF02710170.pdf

Reference26 articles.

1. Faivre J, Bouvier AM, Bonithon-Kopp C. Epidemiology and screening of colorectal cancer. Best Pract Res Clin Gastroenterol. 2002;16:187–99.

2. Haller DG. Update on chemotherapy for advanced colorectal cancer. Oncology (Huntingt). 2001;15:11–5.

3. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol. 1999; 26:589–605.

4. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19:1501–18.

5. García-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8:641–61.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors;Clinical and Translational Science;2022-02-26

2. Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis;European Journal of Cancer;2011-08

3. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer;Anti-Cancer Drugs;2010-09

4. A Randomised Phase II Study of Irinotecan in Combination with 5-FU/FA Compared with Irinotecan Alone as Second-Line Treatment of Patients with Metastatic Colorectal Carcinoma;Oncology Research and Treatment;2007